Trial Profile
Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HTLV-I infections
- Focus Therapeutic Use
- 22 Jan 2018 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 20 Jun 2012 New trial record